+21.3%
TFC vs MRNA
+945.0%
-923.7%
-20.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.0% | +13.1% | -10.2% | +3.1% |
| 7D | +5.1% | +20.6% | -15.6% | +5.2% |
| 30D | +9.8% | +27.1% | -17.3% | +10.1% |
| 3M | -2.4% | +353.4% | -355.8% | -0.9% |
| 6M | +4.9% | +446.3% | -441.3% | +5.4% |
| YTD | +6.6% | +776.2% | -769.6% | +3.4% |
| 1Y | +21.3% | +987.9% | -966.6% | +14.6% |
| All | +21.3% | +945.0% | -923.7% | +14.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling